---
title: "MEDICUS PHARMA LTD C/WTS 15/11/2029(TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -0.43"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252549955.md"
datetime: "2025-08-11T20:26:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252549955.md)
  - [en](https://longbridge.com/en/news/252549955.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252549955.md)
generator: "portal-rs"
---

# MEDICUS PHARMA LTD C/WTS 15/11/2029(TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -0.43

EPS: As of FY2025 Q2, the actual value is USD -0.43.

### Segment Revenue

-   **General and Administrative Expenses**: Increased by $2,299,848 for the three months ended June 30, 2025, compared to the same period in 2024, primarily due to increased legal and accounting fees, salaries, and business development expenses.
-   **Research and Development Expenses**: Increased by $162,406 for the three months ended June 30, 2025, compared to the same period in 2024, primarily due to increased clinical trial activity.

### Operational Metrics

-   **Net Loss**: The net loss for the three months ended June 30, 2025, was $6,176,084, compared to $3,632,859 for the same period in 2024.
-   **Loss from Operations**: Loss from operations for the three months ended June 30, 2025, was $6,016,088, compared to $3,553,834 for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: For the six months ended June 30, 2025, net cash used in operating activities was $9,409,825, compared to $3,953,639 for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: For the six months ended June 30, 2025, net cash provided by financing activities was $14,915,048, compared to $10,642,500 for the same period in 2024.

### Unique Metrics

-   **Accumulated Deficit**: As of June 30, 2025, the accumulated deficit was $40,182,395, which includes deficits from SkinJect, Inc. and Medicus Pharma Ltd.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to continue its SKNJCT-003 study and expand clinical trial sites in Europe and the UAE, with a focus on obtaining FDA approval for its products.
-   **Non-Core Business**: The company entered into a definitive agreement to acquire Antev Limited, which is developing Teverelix for prostate cancer patients, expected to close by August 2025.

### Related Stocks

- [MDCXW.US](https://longbridge.com/en/quote/MDCXW.US.md)

## Related News & Research

- [Does Instacart’s New Exclusivity And Category Expansions Reshape The Bull Case For Maplebear (CART)?](https://longbridge.com/en/news/298119807.md)
- [Why CF Industries (CF) Is Up 6.0% After Blue Ammonia JV and Leadership Transition News](https://longbridge.com/en/news/298114954.md)
- [Is Camtek (CAMT) Options Frenzy Quietly Reframing Its Near‑Term Earnings Story?](https://longbridge.com/en/news/298114664.md)
- [Is Huntington Bancshares (HBAN) Undervalued As Its Growth Narrative Expands?](https://longbridge.com/en/news/298114667.md)
- [Elon Can’t Build His Empire Alone](https://longbridge.com/en/news/298114289.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**